Notícias

The past year's gain was bought with volume and access, and management has already said net price goes lower from here.

Retiring at 65 on dividends sounds straightforward until you realize the number you need today at 55 depends entirely on which yield tier you trust with your financial future, and the wrong choice leaves you no runway to recover.

August's final days are closing a narrow window for income investors, and five blue-chip names with multi-decade dividend streaks just posted earnings beats that change the calculus on each one.

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

The yield you chase to replace a six-figure income determines not just how much capital you need, but whether that income holds up a decade from now or quietly erodes beneath you.

Its growth profile stands well above major sector peers.

Beyond strong drugs, the stock’s ascent was powered by its notable profitability.

Imaavy validates another use for J&J's antibody platform, although the initial patient population remains small.

The FDA approval marks another successful step in J&J’s aim of achieving $5bn in peak sales for the drug.

JNJ's Imaavy wins FDA approval for wAIHA, becoming the first treatment specifically indicated for the rare autoimmune disease.

Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth.

Johnson and Johnson has surged over 54% in a year, cleared a major FDA hurdle, and raised its guidance, yet something about the current setup gives pause before hitting buy.

Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.

While investors fixate on a slowdown in current procedures, hospitals are accelerating their investment in the company's core platform, revealing a crucial, under-appreciated strength.

Jim Cramer declared the data center trade dead on live television and named the stocks he wants instead, but the rotation he described carries a flaw that Wall Street is quietly ignoring.

The yield you chase determines whether you need $1 million or $3.4 million, and the one that feels safest might quietly betray you a decade from now.

Treasuries now yield nearly 5%, raising the stakes for every dividend stock in a boomer portfolio. Five companies have raised their payouts through recessions, inflation spikes, and rate cycles, and the case for owning them lifetime has never required more scrutiny.

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) CEO Anthony Tennyson spoke with Proactive's Stephen Gunnion about the company's £1.3 million fundraising and how proceeds will support its CNS pipeline, spanning SVN-001, SVN-002 and SVN-015. Tennyson said the funding will let Solvonis assess adding international sites to the Phase 3 programme for SVN-001, its severe alcohol use disorder treatment being trialled within the UK's NHS. Including EU sites and data could improve prospects for a European launch or make the programme more attractive to partners. On SVN-002, developed for moderate to severe alcohol use disorder in the US, the company is repurposing esketamine as an oral thin film via the FDA's 505(b)(2) pathway, building a scientific bridge to Johnson & Johnson's Spravato. Discussions with the FDA continue, with Tennyson saying next steps will "hopefully" involve a small toxicology package ahead of a Phase 2 or possible Phase 2b trial. The interview also covered SVN-015, Solvonis' proprietary compound targeting methamphetamine and cocaine addiction, with the US National Institute on Drug Abuse now funding further preclinical work following positive initial screening data. On wider industry interest, Tennyson said: "There are strong tailwinds for the CNS, psychedelics and psychedelic-adjacent industry." Visit Proactive’s YouTube channel for more interviews and market updates. Give the video a like, subscribe to the channel and enable notifications for future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #SolvonisTherapeutics #SVN001 #SVN002 #SVN015 #CNS #Biotech #Pharmaceuticals #DrugDevelopment #AlcoholUseDisorder #AddictionTreatment #Neuropsychiatry #ClinicalTrials #Phase3 #FDA #NIDA #BiotechInvesting #LifeSciences #ProactiveInvestors

In August 2026, a Louisiana jury awarded US$10.00 million in a mesothelioma case linked to decades of talc exposure, assigning Johnson & Johnson over US$1.20 million of the liability while finding its talc products unreasonably dangerous and inadequately labeled regarding asbestos risks. The verdict, one of multiple talc trial losses for Johnson & Johnson alongside a proposed multibillion-dollar settlement, highlights how litigation outcomes continue to shape perceptions of the company’s...

Management is betting on a bigger year than ever, but investors seem to be waiting for a catch.

Chasing a fatter dividend yield can quietly destroy the very income stream you built it to replace. Before you commit a dollar, understand why the yield number that looks most attractive often signals the greatest danger to your principal.

The 2026 Q2 earnings cycle continues to wind down, with the reporting docket starting to get quiet. The period has been another one of positivity, with several companies, including Apple, EMCOR Group, and Johnson & Johnson, all reporting record-breaking results in one way or another.

Building $37,200 a year in dividend income is a math problem first, and the yield tier you choose changes the capital required by hundreds of thousands of dollars in ways most investors never calculate before picking their first stock.

Healthcare is attracting defensive capital while technology valuations face another violent reset.

LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.

Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.

JNJ's pipeline remains a key growth driver, with new launches, late-stage data and approvals supporting momentum through the rest of 2026 and beyond.

Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.

U.S. stocks closed higher on Friday following a massive sell-off in the previous session, driven by a sharp rise in bond yields, while a lack of clarity over the progress in the Middle East kept denting investors' morale.

Patent expirations are forcing Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) to prove that their newer medicines can replace some of their most successful franchises. Pfizer is simultaneously managing declining COVID-19 revenue and approaching losses of exclusivity, while Johnson & Johnson is already contending with the rapid erosion of Stelara. Their latest results suggest […]